JPWO2021100585A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021100585A5
JPWO2021100585A5 JP2021558324A JP2021558324A JPWO2021100585A5 JP WO2021100585 A5 JPWO2021100585 A5 JP WO2021100585A5 JP 2021558324 A JP2021558324 A JP 2021558324A JP 2021558324 A JP2021558324 A JP 2021558324A JP WO2021100585 A5 JPWO2021100585 A5 JP WO2021100585A5
Authority
JP
Japan
Prior art keywords
preparation
genetically modified
cells
antibody
modified lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021558324A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021100585A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/042187 external-priority patent/WO2021100585A1/ja
Publication of JPWO2021100585A1 publication Critical patent/JPWO2021100585A1/ja
Publication of JPWO2021100585A5 publication Critical patent/JPWO2021100585A5/ja
Pending legal-status Critical Current

Links

JP2021558324A 2019-11-20 2020-11-12 Pending JPWO2021100585A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019209891 2019-11-20
PCT/JP2020/042187 WO2021100585A1 (ja) 2019-11-20 2020-11-12 キメラ抗原受容体遺伝子改変リンパ球の調製方法

Publications (2)

Publication Number Publication Date
JPWO2021100585A1 JPWO2021100585A1 (https=) 2021-05-27
JPWO2021100585A5 true JPWO2021100585A5 (https=) 2022-08-26

Family

ID=75981284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021558324A Pending JPWO2021100585A1 (https=) 2019-11-20 2020-11-12

Country Status (2)

Country Link
JP (1) JPWO2021100585A1 (https=)
WO (1) WO2021100585A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024024551A1 (ja) * 2022-07-26 2024-02-01 国立大学法人京都大学 シェディング構造を有する人工受容体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170333480A1 (en) * 2014-11-05 2017-11-23 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
RS61907B1 (sr) * 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
CA2992551A1 (en) * 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
EP4289944A3 (en) * 2015-10-08 2024-03-13 National University Corporation Tokai National Higher Education and Research System Method for preparing genetically-modified t cells which express chimeric antigen receptor
JP7062640B2 (ja) * 2016-07-29 2022-05-06 ジュノー セラピューティクス インコーポレイテッド 抗ｃｄ１９抗体に対する抗イディオタイプ抗体
SG11202000606TA (en) * 2017-07-29 2020-02-27 Juno Therapeutics Inc Reagents for expanding cells expressing recombinant receptors

Similar Documents

Publication Publication Date Title
CN107630006B (zh) 一种制备tcr与hla双基因敲除的t细胞的方法
JP2021164461A (ja) キメラ抗原受容体及び他の受容体の発現に対するｔ細胞
JP2019536461A5 (https=)
US20250084145A1 (en) Method for establishing pluripotent stem cells bearing genes encoding antigen specific t cell receptor
JP2016509840A5 (https=)
JP2022522231A5 (https=)
EP3770251A1 (en) Method for producing natural killer cells
WO2019206326A1 (zh) 改进的t细胞治疗方法
TW202102667A (zh) 用於擴增和分化供過繼性細胞治療之ｔ淋巴細胞和天然殺手（ｎｋ）細胞之方法
Qiu et al. Advances and prospects in tumor infiltrating lymphocyte therapy
JP2022023136A5 (https=)
CN117025530B (zh) 用肿瘤坏死因子受体超家族激动剂扩增肿瘤浸润淋巴细胞（til）的方法
JPWO2021100585A5 (https=)
JP2023509388A5 (https=)
CN101126076A (zh) TGF-β诱导的调节T细胞及其形成方法和应用
JP2024538258A5 (https=)
CN107858352B (zh) 一种shRNA-cluster序列及其表达载体和用途
JP2019508056A5 (https=)
CN114045309A (zh) 一种通用的嵌合抗原受体调节t细胞制备方法及应用
CN104761636B (zh) 一种HLA-A33限制性eEF2表位多肽及其应用
Budiyati et al. Integrating Bioreactor System to Speed Up Tumour Infiltrating Lymphocytes (TILS) Immunotherapy Commercialization
Neagu et al. CAR-T Cells–Main Steps for Obtaining a Proper “Live Drug” Adoptive Therapy
KR20260026056A (ko) 시험관 내에서 유래된 t 세포 모집단, 이의 생성 방법, 및 사용 방법
CN107254440A (zh) Cd4阳性th17t细胞培养方法
Ivanova et al. Induction of antiidiotypic immune response with autologous T-cell vaccine in patients with multiple sclerosis